Mochi Health Compounded GLP-1vsIvim Health Compounded GLP-1

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These hormones slow how fast your stomach empties and signal fullness to the brain, so you eat less without feeling deprived. A Mochi clinician sets your starting dose and titrates it upward over weeks to balance results against side effects.

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These slow gastric emptying and increase satiety signaling, reducing appetite and calorie intake. Ivim providers tailor your dose individually rather than using a fixed schedule, adjusting as tolerated.

Mochi uses the same active molecules studied in landmark trials. In STEP 1, branded semaglutide 2.4 mg produced about 14.9% average body-weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide 15 mg produced about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so trial results for branded drugs are a reference point, not a guarantee. Individual results vary.

Ivim's compounded medications use the same active molecules as branded GLP-1 drugs. In STEP 1, branded semaglutide produced about 14.9% average weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so these are reference points only. Individual results vary.

Most side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting) and tend to ease as your body adjusts and as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. Because the product is compounded, dosing-error and quality risks exist; report unusual symptoms to your clinician promptly. This is educational information, not medical advice.

The most common effects are gastrointestinal (nausea, diarrhea, constipation, fatigue) and usually ease with gradual titration. Serious but uncommon risks include pancreatitis and gallbladder disease. As a compounded product, dosing-error and quality risks exist, so report unusual symptoms to your provider. This is educational information, not medical advice.

Budget about $178/month for semaglutide ($79 membership + $99 medication) or $278/month for tirzepatide ($79 + $199), as of May 2026. A $39 first-month membership promo lowers the initial cost. Insurance does not cover compounded medication, but membership can drop to ~$69/mo with qualifying insurance on the Wellness Plus plan.

Effective combined cost is about $150/month for semaglutide and ~$208/month for tirzepatide as of May 2026, built from a $75/mo membership (first month free) plus medication bundles ($379-$499 for semaglutide, $550-$900 for tirzepatide). HSA/FSA cards and Klarna financing are accepted. Compounded medication is not insurance-covered.

Generally for US adults seeking medical weight management who clear a clinician's telehealth evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and not for use during pregnancy. State availability varies.

For US adults seeking medical weight management who pass Ivim's telehealth clinical evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy. State availability varies.